Last reviewed · How we verify
Laventair
Laventair, marketed by Fundacio Privada Mon Clinic Barcelona, holds a unique position in its therapeutic segment with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging a well-documented mechanism of action and primary indication. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Laventair |
|---|---|
| Also known as | LABA/LAMA |
| Sponsor | Fundacio Privada Mon Clinic Barcelona |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ANTES B+ Clinical Trial (PHASE4)
- Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |